Ping Ping Xing

Nov 29, 2024 | molecular-cancer.biomedcentral.com | Menglei Jin |Jun Fang |Junwen Peng |Xintian Tina Wang |Ping Ping Xing |Kunpeng Jia | +6 more

Tumor-infiltrating lymphocytes (TILs) have emerged as a readily available and effective marker for assessing tumor immune profiles (Fig. 4). The pathological evaluation of TILs offers a convenient approach to identifying patients who are likely to respond favorably to immunotherapy. For instance, a randomized trial found that a TIL level of ≥ 5% could predict a positive response to pembrolizumab.